Literature DB >> 33508517

Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices.

Benjamin A Steinberg1, Zhen Li2, Emily C O'Brien3, Jessica Pritchard2, Derek S Chew3, T Jared Bunch4, Daniel B Mark5, Yelena Nabutovsky6, Melissa A Greiner2, Jonathan P Piccini7.   

Abstract

BACKGROUND: Atrial fibrillation (AF) and heart failure (HF) often accompany one another, and each is independently associated with poor outcomes. However, the association between AF burden and outcomes is poorly understood.
OBJECTIVE: The purpose of this study was to describe the association between device-based AF burden and HF clinical outcomes.
METHODS: We used a nationwide, remote monitoring database of cardiac implantable electronic devices (CIEDs) linked to Medicare claims. We included patients with nonpermanent AF, undergoing new CIED implant, stratified by baseline HF. The outcomes were new-onset HF, HF hospitalization, and all-cause mortality at 1 and 3 years.
RESULTS: We identified 39,710 patients who met inclusion criteria (25,054 with HF; 14,656 without HF). Patients with HF were younger (mean age 76.3 vs 78.5 years; P <.001), more often male (65% vs 54%; P <.001), and had higher mean CHA2DS2-VASc scores (5.4 vs 4.1; P <.001). Among those without HF, increasing device-based AF burden was significantly associated with increased risk of new-onset HF (adjusted hazard ratio [HR] 1.09 per 10% AF burden; 95% confidence interval [CI] 1.06-1.12; P <.001) and all-cause mortality (adjusted HR 1.05 per 10% AF burden; 95% CI 1.01-1.10; P = .012). Among patients with HF, increasing AF burden was significantly associated with increased risk of HF hospitalization (adjusted HR 1.05 per 10% AF burden; 95% CI 1.04-1.06; P <.001) and all-cause mortality (adjusted HR 1.06 per 10% AF burden; 95% CI 1.05-1.08; P <.001).
CONCLUSION: Among older patients with AF receiving a CIED, increasing AF burden is significantly associated with increasing risk of adverse HF outcomes and all-cause mortality.
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmia burden; Atrial fibrillation; Heart failure; Medicare; Outcomes; Remote monitoring

Mesh:

Substances:

Year:  2021        PMID: 33508517      PMCID: PMC8096675          DOI: 10.1016/j.hrthm.2021.01.021

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  17 in total

1.  When Low-Risk Atrial Fibrillation Is Not So Low Risk: Beast of Burden.

Authors:  Benjamin A Steinberg; Jonathan P Piccini
Journal:  JAMA Cardiol       Date:  2018-07-01       Impact factor: 14.676

2.  Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke.

Authors:  Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Adrian F Hernandez; Allan J Walkey; Emelia J Benjamin; Lesley H Curtis; Susan R Heckbert
Journal:  Eur Heart J       Date:  2013-11-25       Impact factor: 29.983

3.  Rhythm control versus rate control for atrial fibrillation and heart failure.

Authors:  Denis Roy; Mario Talajic; Stanley Nattel; D George Wyse; Paul Dorian; Kerry L Lee; Martial G Bourassa; J Malcolm O Arnold; Alfred E Buxton; A John Camm; Stuart J Connolly; Marc Dubuc; Anique Ducharme; Peter G Guerra; Stefan H Hohnloser; Jean Lambert; Jean-Yves Le Heuzey; Gilles O'Hara; Ole Dyg Pedersen; Jean-Lucien Rouleau; Bramah N Singh; Lynne Warner Stevenson; William G Stevenson; Bernard Thibault; Albert L Waldo
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

5.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.

Authors:  David G Jones; Shouvik K Haldar; Wajid Hussain; Rakesh Sharma; Darrel P Francis; Shelley L Rahman-Haley; Theresa A McDonagh; S Richard Underwood; Vias Markides; Tom Wong
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

6.  Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation.

Authors:  Robby Nieuwlaat; Martin H Prins; Jean-Yves Le Heuzey; Panos E Vardas; Etienne Aliot; Massimo Santini; Stuart M Cobbe; Jos W M G Widdershoven; Leo H Baur; Samuel Lévy; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2008-04-07       Impact factor: 29.983

7.  Outcomes of medicare beneficiaries with heart failure and atrial fibrillation.

Authors:  Prateeti Khazanie; Li Liang; Laura G Qualls; Lesley H Curtis; Gregg C Fonarow; Bradley G Hammill; Stephen C Hammill; Paul A Heidenreich; Frederick A Masoudi; Adrian F Hernandez; Jonathan P Piccini
Journal:  JACC Heart Fail       Date:  2014-01-25       Impact factor: 12.035

8.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.

Authors:  Isabelle C Van Gelder; Jeff S Healey; Harry J G M Crijns; Jia Wang; Stefan H Hohnloser; Michael R Gold; Alessandro Capucci; Chu-Pak Lau; Carlos A Morillo; Anne H Hobbelt; Michiel Rienstra; Stuart J Connolly
Journal:  Eur Heart J       Date:  2017-05-01       Impact factor: 29.983

9.  Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.

Authors:  Benjamin A Steinberg; Anne S Hellkamp; Yuliya Lokhnygina; Manesh R Patel; Günter Breithardt; Graeme J Hankey; Richard C Becker; Daniel E Singer; Jonathan L Halperin; Werner Hacke; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Jonathan P Piccini
Journal:  Eur Heart J       Date:  2014-09-10       Impact factor: 29.983

Review 10.  Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review.

Authors:  Hai Deng; Ying Bai; Alena Shantsila; Laurent Fauchier; Tatjana S Potpara; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2017-05-30       Impact factor: 5.460

View more
  5 in total

1.  Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is 'paroxysmal' atrial fibrillation?

Authors:  Benjamin A Steinberg; Zhen Li; Peter Shrader; Derek S Chew; T Jared Bunch; Daniel B Mark; Yelena Nabutovsky; Rashmee U Shah; Melissa A Greiner; Jonathan P Piccini
Journal:  Am Heart J       Date:  2021-11-25       Impact factor: 4.749

2.  Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.

Authors:  Tristram D Bahnson; Anna Giczewska; Daniel B Mark; Andrea M Russo; Kristi H Monahan; Hussein R Al-Khalidi; Adam P Silverstein; Jeanne E Poole; Kerry L Lee; Douglas L Packer
Journal:  Circulation       Date:  2021-12-22       Impact factor: 39.918

3.  Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial.

Authors:  Bao Oanh Nguyen; Harry J G M Crijns; Jan G P Tijssen; Bastiaan Geelhoed; Anne H Hobbelt; Martin E W Hemels; W J Myke Mol; Bob Weijs; Marco Alings; Marcelle D Smit; Robert G Tieleman; Raymond Tukkie; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Europace       Date:  2022-07-15       Impact factor: 5.486

4.  Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Arjun K Pandey; Iva Okaj; Hargun Kaur; Emilie P Belley-Cote; Jia Wang; Alireza Oraii; Alexander P Benz; Linda S B Johnson; Jack Young; Jorge A Wong; Subodh Verma; David Conen; Hertzel Gerstein; Jeff S Healey; William F McIntyre
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501

5.  Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.

Authors:  Kevin L Thomas; Hussein R Al-Khalidi; Adam P Silverstein; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Daniel B Mark; Douglas L Packer
Journal:  J Am Coll Cardiol       Date:  2021-07-13       Impact factor: 27.203

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.